Case ReportCase Report
Regression of Advanced Refractory Ovarian Cancer Treated with Iodine-131-Labeled Anti-CEA Monoclonal Antibody
Malik Juweid, Robert M. Sharkey, Abass Alavi, Lawrence C. Swayne, Thomas Herskovic, Debra Hanley, Arnold D. Rubin, Michael Pereira and David M. Goldenberg
Journal of Nuclear Medicine February 1997, 38 (2) 257-260;
Malik Juweid
Robert M. Sharkey
Abass Alavi
Lawrence C. Swayne
Thomas Herskovic
Debra Hanley
Arnold D. Rubin
Michael Pereira
This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Regression of Advanced Refractory Ovarian Cancer Treated with Iodine-131-Labeled Anti-CEA Monoclonal Antibody
Malik Juweid, Robert M. Sharkey, Abass Alavi, Lawrence C. Swayne, Thomas Herskovic, Debra Hanley, Arnold D. Rubin, Michael Pereira, David M. Goldenberg
Journal of Nuclear Medicine Feb 1997, 38 (2) 257-260;
Regression of Advanced Refractory Ovarian Cancer Treated with Iodine-131-Labeled Anti-CEA Monoclonal Antibody
Malik Juweid, Robert M. Sharkey, Abass Alavi, Lawrence C. Swayne, Thomas Herskovic, Debra Hanley, Arnold D. Rubin, Michael Pereira, David M. Goldenberg
Journal of Nuclear Medicine Feb 1997, 38 (2) 257-260;
Jump to section
Related Articles
- No related articles found.
Cited By...
- 18F-FDG PET/CT for Monitoring the Response of Lymphoma to Radioimmunotherapy
- Blood Pharmacokinetics of Various Monoclonal Antibodies Labeled with a New Trifunctional Chelating Reagent for Simultaneous Conjugation with 1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-Tetraacetic Acid and Biotin before Radiolabeling
- Perspectives on Cancer Therapy with Radiolabeled Monoclonal Antibodies
- Targeted Therapy of Cancer with Radiolabeled Antibodies
- Optimal Quality 131I-Monoclonal Antibodies on High-Dose Labeling in a Large Reaction Volume and Temporarily Coating the Antibody with IODO-GEN
- Two-Step Targeting of Xenografted Colon Carcinoma Using a Bispecific Antibody and 188Re-Labeled Bivalent Hapten: Biodistribution and Dosimetry Studies